期刊文献+

tM2-PK蛋白在结直肠癌中的表达及临床意义 被引量:3

The expression and clinical signification of tM2-PK in colorectal cancer
暂未订购
导出
摘要 目的研究肿瘤型丙酮酸激酶(tM2-PK)在结直肠癌(CRC)患者中的表达及相关性,为CRC的早期诊断、预后判断和治疗后随访,寻求一种简便可靠、无创的检测方法。方法分别应用免疫组化(IHC)法和酶联免疫吸附(ELISA)法检测68例CRC患者癌组织和术前血清tM2-PK水平,并与40例结直肠息肉患者和40例健康体检者作比较。结果①CRC组血清tM2-PK水平明显高于结直肠息肉组、正常组(P<0.05),其表达与肿瘤大小、Duke分期均显著相关;②CRC组织中tM2-PK阳性表达率明显高于结直肠息肉组织和癌旁正常组织(P<0.05),其表达与肿瘤大小、分化程度、Duke分期均显著相关;③血清与癌组织的tM2-PK水平密切相关(r=0.357,P=0.003)。结论血清和癌组织tM2-PK测定对CRC诊断、预后评估及监测有一定的临床意义。 Objective To investigate the expression and clinical signification of tumor M2 pyruvate kinase in pa-tients with CRC, and to try to find a reliable and atraumatic method to predict the progress and pronosis in the CRC. Methods ELISA method was used to determine the serum levels of tM2-PK in 68 patients with CRC,40 pa-tients with colorectal polyps and 40 cases of normal subjects; immunohistochemistry ( IHC ) methods were respec-tively used to detect the expression of tM2-PK in tissues. Results ① The level of serum tM2-PK in patients with CRC was significantly higher than the group of patients with polyps and the normal subjects ( P&lt;0.05 ) . The serum tM2-PK levels was closely correlated to tumor size and Duke stage.②The positive rate of tissue tM2-PK was signif-icantly higher in CRC than in colorectal polyps and normal subjects ( P&lt;0.05 ) . Tissue tM2-PK levels was closely correlated to tumor size,Duke stage and differentiation grade. ③Serum tM2-PK levels was correlated to tissue tM2-PK levels (r=0.357,P=0.003). Conclusion Combined detection of expression of tM2-PK can provide the basis theory for the diagnosis and prognosis evaluation of CRC.
作者 喻鑫 刘弋
出处 《安徽医科大学学报》 CAS 北大核心 2014年第2期236-239,共4页 Acta Universitatis Medicinalis Anhui
基金 国际科技合作计划(编号:1303063016)
关键词 结直肠癌 肿瘤型丙酮酸激酶 免疫组化 酶联免疫吸附试验 colorectal carcinoma tumor M2 pyruvate kinase IHC ELISA
  • 相关文献

参考文献11

  • 1Leporrier J,Maurel J,Chinese L. A population-based study of incidence management and prognosis of hepatic metastases from colorectal cancer[J].{H}British Journal of Surgery,2006,(4):465-474.
  • 2Mazurek S,Boschek C B,Hugo F. Pyruvate Kinase type M2 and its role in tumor growth and spreading[J].Semin Cancer Bi-ol,2005,(4):300-308.
  • 3Luftner D,Meerharm J,Akri C. Tumor type M2 pyruvate ki-nase expression in advanced breast cancer[J].{H}Anticancer Research,2000,(6D):5077-5082.
  • 4Oremek G M,Teigelkamp S,Kramer W. The pyrivate Ki-nase isoenzyme tumor m2(tu tM2-PK)as a tumor marker for renal carcinoma[J].{H}Anticancer Research,1999,(4A):2599-2601.
  • 5倪田根,祝秉东,周欣,王娜,曾峰,关泉林.胃癌组织中ENO1、M2-PK蛋白表达及其临床意义[J].现代生物医学进展,2011,11(20):3871-3874. 被引量:2
  • 6Christofk H R,Vander Heiden M G,Harris M H. The m2 splice isoform of pyruvate Kinase is important for cancer metabo-lism and tumor growth[J].{H}NATURE,2008,(7184):230-233.
  • 7叶维洁,金冶宁.肿瘤型丙酮酸激酶在结直肠癌血浆中的测定及其临床意义[J].现代肿瘤医学,2010,18(3):511-514. 被引量:6
  • 8Fakih M G,Padamanabhan A. CEA monitoring in colorectal canc-er. What you should know [K].{H}ONCOLOGY-BASEL,2006,(6):579-587.
  • 9陆应玉,刘华平.血清肿瘤标志物联合检测在消化道肿瘤诊断中的价值[J].安徽医科大学学报,1999,34(6):458-459. 被引量:1
  • 10Hard P D,Ngoumou B K,Rupp J. Tumor M2-pyruvate ki-nase:a promising tumor marker in the diagnosis of gastro-intestinal cancer[J].{H}Anticancer Research,2000,(6D):4965-4968.

二级参考文献47

  • 1秦晓光.肿瘤标志物应用中的若干问题[J].中华医学检验杂志,1995,18(4):197-198. 被引量:14
  • 2Prakin DM. Global cancer statistics in year 2000 [ J ]. Lancet On- coi,2001,2:533 - 543.
  • 3Sehnerder J, Bitterlich N, Sehulze G. Improved sensitivity in the diagnosis of gastro - intestinal tumors by fuzzy logic - based tumor marker profiles including the tumor M2 -PK [ J ]. Anticaneer Res, 2005.25 (3A) :1507 - 1515.
  • 4Ventrucci M, Cipolla A, Racchini C, et al. Tumor M2 - pyruvate kinase,a new metabolic marker for pancreatic cancer[J].Dig Dis Sci,2004,49(7 -8) :1149 - 1155.
  • 5Schneider J, Morr H, Velcovsky HG, et al. Quantitative detection of tumor M2 - pryuvate kinase in plasma of patients with lung cancer in comparison to other lung diseases [ J]. Cancer Detect Prey, 2000,24(6) :531 -535.
  • 6Schneider J, Neu K, Veleovsky HG, et al. Tumor M2 - pyruvate kinase in the follow - up of inoperable lung cancer patients : a pilot study[ J]. Cancer Lett,2003,193 ( 1 ) :91 - 98.
  • 7Schneider J, Peltri G, Bitterlieh N, et al. Fuzzy logic - based tumor marker profiles improved sensitivity of the detection of progression in small - cell lung cancer patients [ J ]. Clin Exp Med, 2003,2 (4) :185 - 191.
  • 8Oremek GM, Sapoutzis N, Kramer W, et al. Value of tumor M2 ( Tu M2- PK) in patients with renal carcinoma[ J]. Anticancer Res, 2000,20(6D) :5095 -5098.
  • 9Kaura B, Bagga R, Patel FD. Evaluation of the Pyruvate Kinase isoenzyme tumor( Tu M2 -PK) as a tumor marker for cervical careinoma[ J]. J Obstet Gynaeeol Res,2004,30(3 ) : 193 - 196.
  • 10Ugurel S, Bell N, Sucker A, et al. Tumor type M2 pyruvate kinase ( Tu M2. - PK) as a novel plasma tumor marker in melanoma[J]. Int J Cancer,2005,117 ( 5 ) : 825 - 830.

共引文献6

同被引文献27

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部